CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 119 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,470,337 | -25.3% | 158,971 | +8.8% | 0.00% | -33.3% |
| Q2 2023 | $4,644,392 | +49.5% | 146,096 | +14.7% | 0.00% | +50.0% |
| Q1 2023 | $3,107,554 | -19.4% | 127,411 | +4.6% | 0.00% | 0.0% |
| Q4 2022 | $3,853,526 | +16.7% | 121,839 | +3.1% | 0.00% | 0.0% |
| Q3 2022 | $3,301,349 | +7.4% | 118,166 | +3.4% | 0.00% | 0.0% |
| Q2 2022 | $3,074,931 | -16.9% | 114,323 | +4.5% | 0.00% | 0.0% |
| Q1 2022 | $3,699,925 | +469.2% | 109,385 | +452.8% | 0.00% | – |
| Q4 2021 | $650,000 | +9.8% | 19,789 | -1.3% | 0.00% | – |
| Q3 2021 | $592,000 | +14.5% | 20,054 | -0.6% | 0.00% | – |
| Q2 2021 | $517,000 | – | 20,177 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,713,470,000 | 41.39% |
| Perceptive Advisors | 6,511,727 | $184,021,000 | 5.34% |
| Finepoint Capital LP | 536,901 | $15,173,000 | 4.99% |
| Artal Group S.A. | 2,000,000 | $56,520,000 | 2.41% |
| Rock Springs Capital Management LP | 2,499,148 | $70,626,000 | 1.82% |
| Ikarian Capital, LLC | 178,100 | $5,033,000 | 1.00% |
| Hood River Capital Management LLC | 896,572 | $25,337,000 | 0.97% |
| Frazier Life Sciences Management, L.P. | 393,000 | $11,106,000 | 0.86% |
| HighVista Strategies LLC | 23,611 | $667,000 | 0.38% |
| FEDERATED HERMES, INC. | 3,313,333 | $93,635,000 | 0.27% |